WO1997005267A3 - Mucosal delivery of polynucleotides - Google Patents
Mucosal delivery of polynucleotides Download PDFInfo
- Publication number
- WO1997005267A3 WO1997005267A3 PCT/US1996/012041 US9612041W WO9705267A3 WO 1997005267 A3 WO1997005267 A3 WO 1997005267A3 US 9612041 W US9612041 W US 9612041W WO 9705267 A3 WO9705267 A3 WO 9705267A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotide
- animal
- binding protein
- polynucleotides
- mucosal delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9507664A JPH11510164A (en) | 1995-07-26 | 1996-07-19 | Mucosal delivery of polynucleotides |
AU65057/96A AU6505796A (en) | 1995-07-26 | 1996-07-19 | Mucosal delivery of polynucleotides |
CA002227871A CA2227871A1 (en) | 1995-07-26 | 1996-07-19 | Mucosal delivery of polynucleotides |
EP96924664A EP0840796A2 (en) | 1995-07-26 | 1996-07-19 | Mucosal delivery of polynucleotides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US152795P | 1995-07-26 | 1995-07-26 | |
US60/001,527 | 1995-07-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1997005267A2 WO1997005267A2 (en) | 1997-02-13 |
WO1997005267A3 true WO1997005267A3 (en) | 1997-04-24 |
Family
ID=21696500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/012041 WO1997005267A2 (en) | 1995-07-26 | 1996-07-19 | Mucosal delivery of polynucleotides |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0840796A2 (en) |
JP (1) | JPH11510164A (en) |
AU (1) | AU6505796A (en) |
CA (1) | CA2227871A1 (en) |
WO (1) | WO1997005267A2 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69835525T2 (en) * | 1997-03-12 | 2007-03-08 | Idera Pharmaceuticals, Inc., Cambridge | DERIVED REGULATION OF GENE EXPRESSION BY COLORECTAL ADMINISTRATION OF SYNTHETIC OLIGONUCLEOTIDES |
GB9713122D0 (en) * | 1997-06-20 | 1997-08-27 | Chiron Spa | Novel method of DNA transfer into cells |
IL142231A0 (en) * | 1998-09-30 | 2002-03-10 | American Cyanamid Co | Mutant cholera holotoxin as an adjuvant |
US7384640B1 (en) | 1999-09-30 | 2008-06-10 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant |
US7041296B1 (en) * | 1999-11-12 | 2006-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of treating inflammatory bowel disease using cholera toxin B subunit |
EP1404368B1 (en) | 2001-06-07 | 2009-12-09 | Wyeth Holdings Corporation | Mutant forms of cholera holotoxin as an adjuvant |
CN1541111A (en) | 2001-06-07 | 2004-10-27 | ���Ͽع�����˾ | Mutant forms of cholera holotoxin as adjuvant |
CN101143221A (en) * | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | Central airway administration for systemic delivery of therapeutics |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
US8680020B2 (en) | 2008-07-15 | 2014-03-25 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
JP6302909B2 (en) | 2012-08-18 | 2018-03-28 | アカデミア シニカAcademia Sinica | Cell-permeable probes for sialidase identification and imaging |
WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
CN105682666B (en) | 2013-09-06 | 2021-06-01 | 中央研究院 | Activation of human iNKT cells using glycolipids |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
EP3094352B1 (en) | 2014-01-16 | 2020-09-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
EP3129767B1 (en) | 2014-03-27 | 2021-09-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
TWI717319B (en) | 2014-05-27 | 2021-02-01 | 中央研究院 | Fucosidase from bacteroides and methods using the same |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
KR20170003720A (en) | 2014-05-27 | 2017-01-09 | 아카데미아 시니카 | Anti-cd20 glycoantibodies and uses thereof |
TWI679020B (en) | 2014-05-27 | 2019-12-11 | 中央研究院 | Anti-her2 glycoantibodies and uses thereof |
KR102494193B1 (en) | 2014-05-28 | 2023-01-31 | 아카데미아 시니카 | Anti-tnf-alpha glycoantibodies and uses thereof |
CN107001404B (en) | 2014-09-08 | 2021-06-29 | 中央研究院 | Activation of human iNKT cells using glycolipids |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
JP6779887B2 (en) | 2015-01-24 | 2020-11-04 | アカデミア シニカAcademia Sinica | New glycan conjugate and how to use it |
CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
JP7213549B2 (en) | 2016-08-22 | 2023-01-27 | シーエイチオー ファーマ インコーポレイテッド | Antibodies, Binding Fragments, and Methods of Use |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986006635A1 (en) * | 1985-05-15 | 1986-11-20 | Biotechnology Australia Pty. Ltd. | Oral vaccines |
JPS63258493A (en) * | 1987-04-15 | 1988-10-25 | Mitsui Toatsu Chem Inc | Anti-ganglioside gm, monoclonal antibody, cell producing said antibody and reagent composed thereof |
EP0372928A2 (en) * | 1988-12-07 | 1990-06-13 | University Of Leicester | Heat-labile toxin B subunit fusion proteins |
EP0418626A2 (en) * | 1989-09-08 | 1991-03-27 | Takeda Chemical Industries, Ltd. | Fused proteins and production thereof |
WO1991007979A1 (en) * | 1989-11-29 | 1991-06-13 | Center For Innovative Technology | Chimeric proteins |
WO1993019183A1 (en) * | 1992-03-23 | 1993-09-30 | University Of Massachusetts Medical Center | Immunization by inoculatioon of dna transcription unit |
WO1994009823A1 (en) * | 1992-11-03 | 1994-05-11 | Oravax, Inc. | Urease-based vaccine against helicobacter infection |
WO1994023752A1 (en) * | 1993-04-16 | 1994-10-27 | University Of Portsmouth Enterprise Limited | Drug delivery system |
WO1995010301A1 (en) * | 1993-10-08 | 1995-04-20 | Duotol Ab | Immunological tolerance-inducing agent |
US5433946A (en) * | 1991-10-11 | 1995-07-18 | Health Research Inc. | Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases |
-
1996
- 1996-07-19 JP JP9507664A patent/JPH11510164A/en active Pending
- 1996-07-19 CA CA002227871A patent/CA2227871A1/en not_active Abandoned
- 1996-07-19 WO PCT/US1996/012041 patent/WO1997005267A2/en not_active Application Discontinuation
- 1996-07-19 EP EP96924664A patent/EP0840796A2/en not_active Withdrawn
- 1996-07-19 AU AU65057/96A patent/AU6505796A/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986006635A1 (en) * | 1985-05-15 | 1986-11-20 | Biotechnology Australia Pty. Ltd. | Oral vaccines |
JPS63258493A (en) * | 1987-04-15 | 1988-10-25 | Mitsui Toatsu Chem Inc | Anti-ganglioside gm, monoclonal antibody, cell producing said antibody and reagent composed thereof |
EP0372928A2 (en) * | 1988-12-07 | 1990-06-13 | University Of Leicester | Heat-labile toxin B subunit fusion proteins |
EP0418626A2 (en) * | 1989-09-08 | 1991-03-27 | Takeda Chemical Industries, Ltd. | Fused proteins and production thereof |
WO1991007979A1 (en) * | 1989-11-29 | 1991-06-13 | Center For Innovative Technology | Chimeric proteins |
US5433946A (en) * | 1991-10-11 | 1995-07-18 | Health Research Inc. | Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases |
WO1993019183A1 (en) * | 1992-03-23 | 1993-09-30 | University Of Massachusetts Medical Center | Immunization by inoculatioon of dna transcription unit |
WO1994009823A1 (en) * | 1992-11-03 | 1994-05-11 | Oravax, Inc. | Urease-based vaccine against helicobacter infection |
WO1994023752A1 (en) * | 1993-04-16 | 1994-10-27 | University Of Portsmouth Enterprise Limited | Drug delivery system |
WO1995010301A1 (en) * | 1993-10-08 | 1995-04-20 | Duotol Ab | Immunological tolerance-inducing agent |
Non-Patent Citations (8)
Title |
---|
DATABASE MEDLINE XP002027270 * |
LEHNER ET AL.: "Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein", SCIENCE, vol. 258, no. 5036, 1992, pages 1365 - 1369, XP000645284 * |
LYCKE ETAL.: "The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity", EUR. J. IMMUNOL., vol. 22, no. 9, September 1992 (1992-09-01), pages 2277 - 2281, XP002058448, DOI: doi:10.1002/eji.1830220915 * |
NASHAR ET AL.: "Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes", VACCINE, vol. 11, no. 2, 1993, pages 235 - 240, XP000645274 * |
PATENT ABSTRACTS OF JAPAN vol. 013, no. 063 (C - 568) 13 February 1989 (1989-02-13) * |
PILLAI ET AL.: "Translational fusion of heat labile enterotoxin chain B and beta-subunit of human chorionic gonadotropin: periplasmic expression in Escherichiacoil and its immunogenicity", FEBS LETT., vol. 387, no. 1, 27 May 1996 (1996-05-27), pages 23 - 26, XP000645267 * |
ROHRBAUGH ET AL.: "Gene transfer fior therapy and prophylaxis of HIV-1 infection", ANN. NEW YORK ACAD. SCI., vol. 685, 1993, pages 697 - 712, XP000645528 * |
VAN DER HEIJDEN ET AL.: "Manipulation of intestinal immune response against ovalbumin by cholera toxin and its B subunit in mice", IMMUNOLOGY, vol. 72, no. 1, 1991, pages 89 - 93, XP000618947 * |
Also Published As
Publication number | Publication date |
---|---|
JPH11510164A (en) | 1999-09-07 |
WO1997005267A2 (en) | 1997-02-13 |
EP0840796A2 (en) | 1998-05-13 |
AU6505796A (en) | 1997-02-26 |
CA2227871A1 (en) | 1997-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997005267A3 (en) | Mucosal delivery of polynucleotides | |
EG18726A (en) | 1-Nitro-2,2 diaminoethylene derivatives and their use in pest control. | |
AU2993297A (en) | Treatment of sickle cell disease, treatment of immune system diseases and other diseases normally associated with sickle cell anemia | |
AU5817496A (en) | Process for producing erythropoietin containing no animal pr oteins | |
PL319021A1 (en) | Body weight modulators, appropriate nucleic acid and proteins and their diagnostic and therapeutic application | |
ZA947122B (en) | Drug binding protein. | |
WO2002084298A3 (en) | Medicaments which are modulators of hm74 and/or hm74a activity | |
EP0681585A4 (en) | Tata-binding protein associated factors, nucleic acids encoding tafs, and methods of use. | |
AU5229793A (en) | Novel extracts of cucurbita sp., process for their preparation and use in medicaments and in cosmetics | |
EP0147146A3 (en) | Enhancement of transdermal drug delivery | |
IL113373A0 (en) | A plant gene for resistance to vascular diseases and protein encoded thereby | |
AU3477295A (en) | Modified proteins | |
AU5675794A (en) | Mucosal vascular addressin, dna and expression | |
EP0181634A3 (en) | Synthetic gene for human lysozyme | |
EP0853486A4 (en) | Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases | |
WO1999002143A3 (en) | Medicament comprising adenosine | |
AU5008296A (en) | Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy | |
AU6128896A (en) | Isoindole derivatives, their preparation and their application in therapy | |
EP0481673A3 (en) | Genes encoding the human fk-506 binding protein and a s. cerevisiae homolog, fkb1, and their expression | |
WO1996004011A3 (en) | Novel compound to mimic a naturally occurring peptide's effect | |
EP0811687A3 (en) | Polypeptides having l-asparaginase activity | |
AU4751990A (en) | Nucleotides encoding human b1, 4-galactosyltransferase and uses thereof | |
EP0273778A3 (en) | Synergistic behavior of csf-1 and g-csf | |
EP0647454A3 (en) | Rate responsive pacemaker with improved rate change dynamics and pacing method. | |
NZ332688A (en) | Stimulation of host defence mechanisms against tumors using interferon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2227871 Country of ref document: CA Ref country code: JP Ref document number: 1997 507664 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2227871 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996924664 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996924664 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996924664 Country of ref document: EP |